Golden Finance News | Biomedical stocks are showing strong performance, with LK Medical (02105) up 26.26%, AMS Vaccine (06660) up 19.76%, Yiming Onco (01541) up 7.04%, Hansoh Pharma (03692) up 6.4%, Hutchmed (China) (00013) up 6.91%, Peijia Medical (09996) up 5.75%, Akeso (09926) up 5.77%.
BOCOM Intl stated that the tenth batch of drug procurement documents show historically high thresholds and the highest proportion of injections. It is expected that the competition will be exceptionally fierce, but for most prescription drug companies, there are relatively few major varieties involved, and the impact may be limited. The bank advises to wait for the final list of varieties. Recently, the pharmaceutical sector has experienced significant fluctuations in market sentiment, but considering that the sector valuation was already at historical lows, the bank believes there is still room for further recovery. The bank continues to focus on recommending short-term catalyst-rich innovative drug symbols such as Simcere Pharma, Hutchmed (China), Yunding Xinyao, Conova, and Akeso, which have significant profit growth or clear profit break-even points with high valuation repair elasticity. It also suggests paying attention to: 1) privately-owned medical services and medical aesthetics symbols with strong consumer attributes; 2) small and medium-sized innovative drug companies with large deviations between market cap and fundamentals, as their rebound potential after improved liquidity will be quite significant.
GTJA stated that tightening policy expectations have formed in Q3, with relatively stable expectations for Q4, recommending the themes of innovation and improvement. Focusing on companies that emphasize both innovation and commercialization, with significant product differentiation advantages and higher levels of innovation. In 2024 Q4 to 2025 H1, orders and growth rates are expected to recover; performance expectations are stable.
